Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease ; volume:9 ; number:1 ; day:26 ; month:3 ; year:2019 ; pages:1-7 ; date:12.2019
Scientific reports ; 9, Heft 1 (26.3.2019), 1-7, 12.2019

Classification: Naturwissenschaften

Creator: Jasiecki, Jacek
Limon-Sztencel, Anna
Żuk, Monika
Chmara, Magdalena
Cysewski, Dominik
Limon, Janusz
Wasąg, Bartosz

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-019-41578-3

URN: urn:nbn:de:101:1-2019041401115717196808

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Jasiecki, Jacek
Limon-Sztencel, Anna
Żuk, Monika
Chmara, Magdalena
Cysewski, Dominik
Limon, Janusz
Wasąg, Bartosz
SpringerLink (Online service)

Other Objects (12)

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores

Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Related objects

Reset password